My take: sales growth is strong, but the 50% paint promise needs a big H2. Chemicals will stay weak for now. Watch paint market share next quarter.
(Not investment advice)
What do you think of Birla Opus? 👇
I read Grasim's Q2 call so you don't have to 🧵
Record sales, but profit was hit by one big charge. Birla Opus (its paint business) is the story. Here's what management said 👇
6/ The worry: chemicals. Caustic soda is at a 5-year low price ($390/tonne) and the epoxy margin is squeezed. Fibre profit also fell from last quarter as sulfur and pulp got costlier.
My take: orders and the backlog look strong, but the weak cash flow and the delay in turning HVDC work into bills are what I'd watch next quarter. Strong demand is not the same as cash in hand.
What would you track? 👇
(Not investment advice)
I read Hitachi Energy India's Q2 call so you don't have to 🧵
Orders are up 86% and sales up 63%. But there is one number on the cash side that I would not ignore. Here's the full picture 👇
5/ What's next: management expects 4 to 5 more HVDC projects in the next 12 to 24 months. They would not give any guidance on next quarter's orders and said not to treat ₹4,121 cr as a "run rate".
New large transformer plant targeted for 2028.
2/ Guidance raised: this year's profit now ₹775–800 cr, up from ₹700–750 cr. Sales guidance unchanged at ₹3,400–3,500 cr.
The CEO said Q3 looks good and Q4 looks weaker. He called the 30.4% margin a sustainable base.
I read Natco Pharma's Q2 call so you don't have to 🧵
Profit guidance for this year went UP, even though sales are down 30% from last year. Here's why 👇
1/ The numbers: Q2 sales ₹1,019 cr, up 28% from last quarter but down 30% from a year ago. Profit ₹202.6 cr. Profit margin 30.4%.
The fall is because its old star drug, lenalidomide (a cancer medicine), is selling much less.
Grey market premium (an unofficial price people pay before listing) is ₹45–48, around 16–18% above the IPO price.
But GMP can change fast and is not a guarantee. Read the prospectus first.
(Not investment advice)